Bank of America
ALLO icon

Bank of America’s Allogene Therapeutics ALLO Stock Holding History

Bank of America’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.21M Buy
2,134,473
+1,127,145
+112% +$2.26M ﹤0.01% 3428
2025
Q4 		$1.38M Buy
1,007,328
+33,008
+3% +$43.5K ﹤0.01% 4333
2025
Q3 		$1.21M Sell
974,320
-13,175
-1% -$15.7K ﹤0.01% 5194
2025
Q2 		$1.12M Buy
987,495
+38,686
+4% +$51.4K ﹤0.01% 5231
2025
Q1 		$1.39M Sell
948,809
-214,934
-18% -$405K ﹤0.01% 4991
2024
Q4 		$2.48M Buy
1,163,743
+579,818
+99% +$1.43M ﹤0.01% 4254
2024
Q3 		$1.63M Buy
583,925
+151,222
+35% +$403K ﹤0.01% 4712
2024
Q2 		$1.01M Buy
432,703
+28,321
+7% +$83.5K ﹤0.01% 4902
2024
Q1 		$1.81M Buy
404,382
+73,494
+22% +$307K ﹤0.01% 4520
2023
Q4 		$1.06M Sell
330,888
-505,579
-60% -$1.43M ﹤0.01% 4942
2023
Q3 		$2.65M Buy
836,467
+120,998
+17% +$530K ﹤0.01% 4001
2023
Q2 		$3.56M Sell
715,469
-316,195
-31% -$1.71M ﹤0.01% 3708
2023
Q1 		$5.1M Buy
1,031,664
+167,186
+19% +$1.07M ﹤0.01% 3532
2022
Q4 		$5.44M Buy
864,478
+500,817
+138% +$4.64M ﹤0.01% 3318
2022
Q3 		$3.93M Buy
363,661
+95,669
+36% +$1.3M ﹤0.01% 3591
2022
Q2 		$3.06M Sell
267,992
-311,934
-54% -$2.77M ﹤0.01% 3913
2022
Q1 		$5.28M Buy
579,926
+310,292
+115% +$3.23M ﹤0.01% 3563
2021
Q4 		$4.02M Buy
269,634
+211,768
+366% +$3.74M ﹤0.01% 3876
2021
Q3 		$1.49M Sell
57,866
-105,235
-65% -$2.5M ﹤0.01% 4708
2021
Q2 		$4.25M Buy
163,101
+104,178
+177% +$2.97M ﹤0.01% 3666
2021
Q1 		$2.08M Sell
58,923
-280,345
-83% -$9.46M ﹤0.01% 4226
2020
Q4 		$8.56M Buy
339,268
+296,300
+690% +$9.66M ﹤0.01% 2630
2020
Q3 		$1.62M Sell
42,968
-5,505
-11% -$208K ﹤0.01% 3844
2020
Q2 		$2.08M Buy
48,473
+19,370
+67% +$701K ﹤0.01% 3598
2020
Q1 		$565K Buy
29,103
+601
+2% +$14.3K ﹤0.01% 4426
2019
Q4 		$740K Sell
28,502
-9,016
-24% -$248K ﹤0.01% 4715
2019
Q3 		$1.02M Sell
37,518
-33,470
-47% -$953K ﹤0.01% 4525
2019
Q2 		$1.91M Sell
70,988
-23,954
-25% -$667K ﹤0.01% 4071
2019
Q1 		$2.75M Buy
94,942
+74,509
+365% +$2.16M ﹤0.01% 3733
2018
Q4 		$551K Buy
+20,433
New +$543K ﹤0.01% 4869

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's ALLO Position: Q1 2026 in Review

Bank of America increased its Allogene Therapeutics (ALLO) stake by 112% in Q1 2026, buying an estimated $2.26M and bringing the position to 2,134,473 shares worth $5.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3428.

Bank of America first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $8.56M in Q4 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Bank of America held 2,134,473 shares of Allogene Therapeutics worth $5.21M as of Q1 2026.
  • Bank of America bought 1,127,145 Allogene Therapeutics shares in Q1 2026, an estimated $2.26M.
  • Allogene Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3428 holding.
  • Bank of America first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • Bank of America's Allogene Therapeutics position peaked at $8.56M in Q4 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.